RNS60

Phase 2Small molecule

Mario Negri Institute for Pharmacological Research

RNS60 is one of 128 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

AsthmaActive, not recruiting

StrokePhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Cinqair

Teva

Preclinical

13 6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 7

RNS60

Mario Negri Institute for Pharmacological Research

Phase 2

3 8

Asmanex

Novartis

Preclinical

5 9

Celexa

AbbVie

Preclinical

1 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Amyotrophic Lateral Sclerosis

NCT02988297

Clinical

Trials by Indication[1]

Asthma3 trials

Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

Completed·RRevalesio Corporation·Phase 1·NCT01511302·65 enrolled

Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge

Completed·RRevalesio Corporation·Phase 2·NCT02422121·30 enrolled

Safety Study of Nebulized RNS60 to Treat Asthma.

Completed·RRevalesio Corporation·Phase 1·NCT01057498·36 enrolled

Amyotrophic Lateral Sclerosis2 trials

Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

Not yet recruiting·RRevalesio Corporation·Phase 2·NCT02988297·140 enrolled

A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

Completed·—·Phase 1·NCT02525471·24 enrolled

Function2 trials

Study of RNS60 on Pain and Function After Hip Labral Repair

Withdrawn·RRevalesio Corporation·Phase 2·NCT02005523

Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery

Withdrawn·RRevalesio Corporation·Phase 2·NCT01922427

Systemic1 trial

Systemic Bioactivity of Inhaled Nebulized RNS60

Completed·RRevalesio Corporation·Phase 1·NCT02490865·56 enrolled

Pilot Study1 trial

Pilot Study of RNS60 in Allergen-induced Bronchoconstriction

Withdrawn·RRevalesio Corporation·Phase 2·NCT02497222

4 more indications

Stroke1 trial

Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Completed·RRevalesio Corporation·Phase 2·NCT04693715·83 enrolled

Biomarkers1 trial

The Effect of RNS60 on ALS Biomarkers

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT03456882·147 enrolled

Multiple Sclerosis1 trial

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Withdrawn·RRevalesio Corporation·Phase 2·NCT01714089

Unspecified1 trial

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Completed·RRevalesio Corporation·Phase 1·NCT01264783·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for RNS60. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RNS60 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RNS60. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mario Negri Institute for Pharmacological Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Mario Negri Institute for Pharmacological Research

RNS60

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Asthma3 trials

Amyotrophic Lateral Sclerosis2 trials

Function2 trials

Systemic1 trial

Pilot Study1 trial

Stroke1 trial

Biomarkers1 trial

Multiple Sclerosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News